US/UK/Canada

Share

Contacts

  • Immunovia AB
    Medicon Village Scheelevägen 8 SE-223 63 Lund
    +46 46 275 60 00
    http://www.immunovia.com
    • Pick a time period -
    Tags ( Active)

    Immunovia publishes the Annual Report for 2024

    LUND, SWEDEN – Immunovia AB (publ) today announced that the Annual Report for 2024 has been published.   The annual report can be downloaded in pdf format and is available on Immunovia’s website.   For more information, please contact: Jeff Borcherding  CEO and President  jeff.borcherding@immunovia.com     Immunovia in brief    Immunovia AB (IMMNOV: Nasdaq Stockholm), is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of

    The exercise period for warrants series TO 3 begins today

    Today, 1 April 2025, the exercise period for warrants series TO 3 in Immunovia AB (publ) (“Immunovia” or the “Company”) (the “Warrant Programme”) begins. The exercise period runs until 15 April 2025.   Summarized terms for the warrants of series TO 3 · Structure: One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company. · Exercise period: 1 April 2025 – 15 April 2025. · Subscription price: SEK 0.24 per share. · Issue volume: 62,211,989 warrants series TO 3. Upon full exercise, 62,211,989 shares will be issued and the Company will

    Immunovia announces determined exercise price for warrants series TO 3

    Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that the exercise price for warrants series TO 3 (the “warrants”) has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in the warrants is 11 April 2025. Immunovia carried out a rights issue of units during August – September 2024 (the “Rights Issue”). Each unit issued in the Rights Issue consisted of two (2) shares, two (2) warrants series TO 2 and one (1) warrant series TO 3. One (1) warrant series TO 3

    Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially.  Immunovia’s next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target

    Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.     Jeff Borcherding, Immunovia CEO and Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs will present additional study results and share implications of the study.    The webcast will be held in English and will offer attendees the opportunity to ask questions. Here is

    Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of stage I and II cases of pancreatic cancer.   “The high accuracy of the Immunovia test in detecting stage I and II PDAC in a second independent clinical population of high-risk patients is very encouraging,” said Dr. Patricio Polanco, Co-Director of the Pancreatic Cancer

    Immunovia’s CLARITI study results selected for prestigious presentation at the world’s largest gastroenterology conference

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week[®] (DDW) 2025 conference, taking place May 5, 2025. The CLARITI study was selected as one of only six abstracts to be presented at the AGA Institute Council’s Pancreatic Disorders Section Distinguished Abstract Plenary—an honor reserved for research demonstrating exceptional scientific and clinical impact. Dr. Aimee Lee Lucas, Chief of

    Immunovia Publishes Full Year Report for 2024

    October-December 2024 · Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155). · Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc. · Operating losses were -30,1 MSEK (-23,4). · Earnings per share before and after dilution were 0.02 SEK (-1,08). · Cash flow from operating activities amounted to -28,3 MSEK (-28,5). · Cash and cash equivalents at end of period equaled 25,3 MSEK (76,8). · On October 2, the company

    Immunovia initiates search for a new CFO to support commercialization in the USA

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that it will be hiring a new Chief Financial Officer (CFO) as its focus turns to the US market. As Immunovia transitions to commercializing its test in the second half of 2025, the company’s financial leadership needs are changing. The launch of Immunovia’s pancreatic cancer test in the USA creates a need for deeper expertise and relationships in the US diagnostics market as well as global capital markets. The company is conducting a search for a CFO with diagnostics or med

    Invitation to Immunovia’s Q4 presentation

    LUND (SWEDEN) – Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com   Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and webcast Call

    Change in number of shares and votes in Immunovia AB (publ)

    During January 2025, the registered number of shares and votes in Immunovia AB (publ) (”Immunovia”) has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to 261,908,863.   For further information, please contact Jeff Borcherding, CEO jeff.borcherding@immunovia.com   Karin Almqvist Liwendahl, CFO karin.almqvist.liwendahl@immunovia.com   +46 70 911 56 08   This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial

    Immunovia AB announces outcome of exercise of warrants series TO 2

    The exercise period for warrants series TO 2 (the “Warrant Programme”) in Immunovia AB (publ) (“Immunovia” or the “Company”) ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 percent. Thus, no guarantee commitments need to be utilized.   Jeff Borcherding, CEO of Immunovia, comments: “We are thankful and appreciate the investment in Immunovia by those who exercised warrants. We will utilize this capital to prepare for the introduction of our next-generation

    Immunovia AB (Publ) presents Nomination Committee

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company’s Nomination Committee.   According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which three should be appointed by the Company's three largest shareholders in terms of votes, and the fourth shall be the Chair of the Board of Directors.   The Nomination Committee will consist of the following persons who together represent 5,65 percent of the number of

    The exercise period for warrants of series TO 2 beings today

    Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) (“Immunovia” or the “Company”) (the “Warrant Programme”) begins. The exercise period runs until 16 January 2025.   Summarized terms for the warrants of series TO 2 · Structure: One (1) warrant series TO 2 entitles the holder to subscribe for one (1) new share in the Company. · Exercise period: 2 January 2025 – 16 January 2025. · Subscription price: SEK 0.46 per share. · Issue volume: 124,423,978 warrants of

    Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme

    Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that the exercise price for warrants series TO 2 (the “warrants”) has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading in the warrants is 14 January 2025. In addition to the subscription intentions from the Company’s CEO and board members, which were announced on 18 December 2024, encompassing approximately SEK 0.8 million, Immunovia has received a subscription commitment of approximately SEK 0.1 million and

    Immunovia discovery study published in top protein research journal

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the largest and most comprehensive pancreatic cancer proteomics study done to date.   The discovery study identified 41 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC), the most common form of

    End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding

    LUND (SWEDEN) – As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025.   In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success   As 2024 began, we had recently completed a significant transformation of the company. We were a much smaller, more agile team focused on the development of our next-generation test. This focus—and the talents of the Immunovia team—drove excellent progress in 2024. Key highlights:   · We developed accurate and reliable lab

    Immunovia CEO and board members announce intention to fully exercise their TO2 warrants

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company’s rights issue that was announced on May 20, 2024. Immunovia CEO Jeff Borcherding, one of the company’s largest shareholders based on prior purchases, intends to exercise all warrants he purchased in the recent rights issue. In addition, all board members who currently hold TO2 warrants, Martin Møller, Hans Johansson and Peter Høngaard Andersen, have communicated their intention to fully

    Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET.     Jeff Borcherding, CEO, Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs and Lisa Ford, PhD, Laboratory Director will present additional details about the results and the implications of the study. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai and

    Immunovia announces financial calendar for financial year 2025/2026

    LUND, SWEDEN – Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026. Year-End 2024 Report             February 25, 2025  Q1 Report, 2025                     May 14, 2025  Q2 Report, 2025                     August 21, 2025  Q3 Report, 2025                     November 19, 2025 Year-End 2025 Report             February 24, 2026   The Annual General Meeting will be held on May 14, 2025, 11:00 CET. For more information, please contact:Karin

    Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).   In the study of over 1,000 patient samples, the test achieved the primary endpoint, exceeding the predefined accuracy criteria and marking a critical milestone in Immunovia’s mission to increase patient survival through early detection of pancreatic cancer.   Key findings from

    Immunovia to present at the Redeye Technology & Life Science Day

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3, hosted by Redeye.   Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking work of these companies. During the event, Immunovia CEO Jeff Borcherding will be present in Stockholm to share the company’s latest developments.   Event attendees are encouraged to take the opportunity to meet with Jeff and Immunovia’s CFO, Karin Almqvist-

    Immunovia Publishes Interim Report for January-September 2024

    July-September 2024 · Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488). · Net earnings amounted to -51.1 MSEK (-38.6). · Earnings per share before and after dilution were -0.73 SEK (-0.91). · Cash flow from operating activities amounted to -21.2 MSEK (-35.6). · Cash and cash equivalents at end of period amounted to 54.2 MSEK (106.7) · New lab staffed and fully operational after rapid implementation and validation was announced on July 2. · Detailed discovery study results for the company’s next-generation early detection test for

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media